Stock listing
Senhwa Biosciences Inc
Selected listing: 6492 · TPEX · TWD · TW
Senhwa Biosciences Inc (TPEx:6492), Commercial Services. Latest release Aug 25, 2026: Senhwa Completes Enrollment in Phase 1b CX-5461 Expansion Trial; CSR…
- Ticker
- TPEx:6492
- Asset type
- Stock
- Sector
- Commercial Services
- Industry
- Miscellaneous Commercial Services
- Exchange
- TPEx
- Currency
- TWD
About Senhwa Biosciences Inc
Senhwa Biosciences Inc is a public company listed on the Taiwan stock market under the ticker 6492. Senhwa focuses on developing innovative therapies to address unmet medical needs.
Latest news from Senhwa Biosciences Inc
Senhwa Completes Enrollment in Phase 1b CX-5461 Expansion Trial; CSR Expected in Q1 2027
August 25, 2026
Senhwa's CX-5461 Opens a New Frontier in Photoimmunotherapy; Multinational Study Published in Nucleic Acids Research
August 12, 2026
GEM and Senhwa Biosciences have formally executed a Share Purchase Agreement for up to NT$500 million
July 15, 2026
Senhwa Biosciences Launches Global Study, Targeting Breakthrough in Hard-to-Treat Cancers with CX-5461 and Tislelizumab Combination
May 5, 2026
Senhwa Biosciences Secures Strategic Backing from Global Investor GEM with Up to NT$500 Million to Accelerate AI-Driven Drug Development
April 14, 2026
Research Senhwa Biosciences Inc
Senhwa Biosciences Inc company profile
View the public company page for Senhwa Biosciences Inc on 6ix.
Senhwa Biosciences Inc news
Read company news and market updates connected to Senhwa Biosciences Inc.
Senhwa Biosciences Inc investor events
Find investor webinars, events, and replay context for Senhwa Biosciences Inc.